GlassScriptPhysician profile
Rajveer S Sachdev
NPI 1275624660
$210,559.27
in general payments reported to CMS, 2019-2025
37 companies · $92K in 2025
The $92K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $1,931 · 2021: $2,128 · 2022: $2,350 · 2023: $44K · 2024: $67K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $155K · Travel and Lodging: $32K · Food and Beverage: $14K · Consulting Fee: $900 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $155,208.00 |
| Travel and Lodging | $32,364.52 |
| Food and Beverage | $14,294.91 |
| Consulting Fee | $900.00 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $193,179.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $3,213.89 | 2024-2025 | Korlym |
| Novo Nordisk INC | $2,902.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,488.96 | 2019-2025 | Breztri, Farxiga, Tezspire |
| Abbvie INC. | $1,265.93 | 2021-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $1,159.94 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,033.25 | 2019-2025 | Jardiance |
| Pfizer INC. | $967.97 | 2020-2025 | |
| Glaxosmithkline, LLC. | $856.56 | 2019-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $344.19 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $340.73 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $313.31 | 2019-2023 | Livalo |
| Currax Pharmaceuticals LLC | $305.22 | 2019-2025 | Contrave, Nexletol |
| Sanofi-Aventis U.S. LLC | $299.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $255.08 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajveer Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.